Journal article Open Access

Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists.

O'Brien-Brown, James; Jackson, Alexander; Reekie, Tristan A; Barron, Melissa L; Werry, Eryn L; Schiavini, Paolo; McDonnell, Michelle; Munoz, Lenka; Wilkinson, Shane; Noll, Benjamin; Wang, Shudong; Kassiou, Michael

Here we report adamantyl cyanoguanidine compounds based on hybrids of the adamantyl amide scaffold reported by AstraZeneca and cyanoguanidine scaffold reported by Abbott Laboratories. Compound 27 displayed five-fold greater inhibitory potency than the lead compound 2 in both pore-formation and interleukin-1β release assays, while 35-treated mice displayed an antidepressant phenotype in behavioral studies. This SAR study provides a proof of concept for hybrid compounds, which will help in the further development of P2X7R antagonists.

Files (834.2 kB)
Name Size
O'Brien-Brown_EurJMedChem_2017-P19-AAM.pdf
md5:2d57806829ce3f02e0ecc7c9fbb540df
834.2 kB Download
40
25
views
downloads
Views 40
Downloads 25
Data volume 20.9 MB
Unique views 39
Unique downloads 24

Share

Cite as